Table 2 Information for radiogenetic/radiogenomic studies
From: Genetics and genomics of radiotherapy toxicity: towards prediction
Category | Information |
|---|---|
Tumor | Type, stage (tumor, node, metastases (TNM)), pathology, volume |
Patient | Age, smoking history, alcohol use, ethnicity, weight, height, breast volume for breast patients (cup size), co-morbidity (for example, diabetes, collagen vascular disease, hypertension, inflammatory bowel disease) |
Treatment | Total dose, number of fractions, dose per fraction, overall treatment time, use of chemotherapy, use of hormone therapy, use of surgery and postoperative complications, concurrent medications (for example, statins) |
Physics | Total radiation dose, dose per fraction, overall treatment time, planned doses to critical normal tissues |
Toxicity | Pre-treatment data and collection a minimum at end of treatment, 6 months and then yearly. Use of site-specific patient-reported toxicity preferable as primary endpoints as physician-reported toxicity underestimates toxicity. Physician-reported toxicity |